SCHEMBL5525324

SCHEMBL5525324

COc1ccc(C(O)C[N+](=O)[O-])cc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.63
CYP2C19 P33261 2/20 0.63
MAPT P10636 4/20 0.52
KDM4E B2RXH2 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
NFKB1 P19838 2/20 0.51
LMNA P02545 2/20 0.50
PPARG P37231 1/20 0.50
PPARD Q03181 1/20 0.50
PPARA Q07869 1/20 0.50
HTT P42858 2/20 0.47
ACHE P22303 1/20 0.47
CYP3A4 P08684 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5518745 1.00 ALDH1A1 (0.63) ALDH1A1CYP2C19MAPTKDM4ESMN1; SMN2
SCHEMBL23549436 0.88 LMNA (0.64) ALDH1A1CYP2C19MAPTKDM4ESMN1; SMN2
SCHEMBL17357757 0.88 ALDH1A1 (0.50) ALDH1A1CYP2C19MAPTKDM4ESMN1; SMN2
SCHEMBL27143021 0.83 ALDH1A1 (0.60) ALDH1A1CYP2C19MAPTSMN1; SMN2NFKB1
SCHEMBL5531387 0.81 ALDH1A1 (0.49) ALDH1A1CYP2C19MAPTKDM4ESMN1; SMN2
SCHEMBL5526206 0.81 ALDH1A1 (0.49) ALDH1A1CYP2C19MAPTKDM4ESMN1; SMN2
SCHEMBL6167182 0.80 ALDH1A1 (0.58) ALDH1A1CYP2C19MAPTKDM4ESMN1; SMN2
SCHEMBL3042994 0.79 CYP2C19 (0.52) ALDH1A1CYP2C19MAPTKDM4ESMN1; SMN2
SCHEMBL10678849 0.79 ALDH1A1 (0.62) ALDH1A1CYP2C19MAPTKDM4ESMN1; SMN2
SCHEMBL10335590 0.78 PPARG (0.61) CYP2C19SMN1; SMN2NFKB1PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050148801-A1 Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof JNC CORPORATION (JP) 2005-07-07 US claimed
US-20020193447-A1 Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof JNC CORPORATION (JP) 2002-12-19 US claimed
EP-0947498-A1 OPTICALLY ACTIVE NITRO ALCOHOL DERIVATIVES, OPTICALLY ACTIVE AMINO ALCOHOL DERIVATES, AND PROCESS FOR PREPARING THE SAME CHISSO CORPORATION (JP) 1999-10-06 EP claimed
US-7205425-B2 Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof CHISSO CORPORATION (JP) 2007-04-17 US disclosed
US-20070060656-A1 Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof SHIBASAKI MASAKATSU 2007-03-15 US disclosed
US-20050148801-A1 Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof JNC CORPORATION (JP) 2005-07-07 US disclosed
US-6632955-B1 Optically active 1-substituted phenyl-2-nitro alcohol derivatives which are useful pharmaceutical intermediates. Enantiomotphs active 1-substituted phenyl-2-nitro alcohol derivatives. From these nitro alcohol such as albutramin and CHISSO CORPORATION (JP) 2003-10-14 US disclosed
US-20020193447-A1 Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof JNC CORPORATION (JP) 2002-12-19 US disclosed
EP-0947498-A1 OPTICALLY ACTIVE NITRO ALCOHOL DERIVATIVES, OPTICALLY ACTIVE AMINO ALCOHOL DERIVATES, AND PROCESS FOR PREPARING THE SAME CHISSO CORPORATION (JP) 1999-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148801-A1 Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof ADH1A, ALDH7A1, ADRB1 ALDH1A1 29/4885CYP2C19 150/4885MAPT 2856/4885
US-20070060656-A1 Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof ADH1A, ALDH7A1, ADRB1 ALDH1A1 29/4885CYP2C19 150/4885MAPT 2856/4885
US-20020193447-A1 Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof ADH1A, ALDH7A1, SARM1 ALDH1A1 24/4885CYP2C19 145/4885MAPT 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.